ArticleCell reports. Medicine2023

Genetic and pharmaceutical targeting of HIF1α allows combo-immunotherapy to boost graft vs. leukemia without exacerbation graft vs. host disease.

Christopher Bailey et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.